These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 34787835)

  • 21. New prospects for the management of cardiovascular effects of tyrosine kinase inhibitors in patients with chronic myeloid leukemia.
    Almeida AG; Almeida A; Melo T; Guerra L; Lopes L; Ribeiro P; Duarte M; Mota A; Fontes-Carvalho R
    Rev Port Cardiol (Engl Ed); 2019 Jan; 38(1):1-9. PubMed ID: 30686651
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Novelties and experience with tyrosine kinase inhibitor therapy in chronic myeloid leukemia].
    Gaál-Weisinger J; Mucsi O; Körösmezey G; Szili B; Eid H; Kiss R; Bödör C; Tárkányi I; Nagy Z; Demeter J
    Magy Onkol; 2017 Mar; 61(1):67-74. PubMed ID: 28273190
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cardiovascular toxicities of BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia: preventive strategies and cardiovascular surveillance.
    Aghel N; Delgado DH; Lipton JH
    Vasc Health Risk Manag; 2017; 13():293-303. PubMed ID: 28831263
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Anxiety and depression associated with tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia.
    Sogawa R; Kimura S; Yakabe R; Mizokami Y; Tasaki M; Sueoka-Aragane N; Narisawa Y; Kimura S
    Int J Clin Oncol; 2018 Oct; 23(5):974-979. PubMed ID: 29651584
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Cardiovascular management of patients with chronic myeloid leukemia from a multidisciplinary perspective, and proposing action protocol by consensus meeting].
    García-Gutiérrez V; Jiménez-Velasco A; Gómez-Casares MT; Sánchez-Guijo F; López-Sendón JL; Steegmann Olmedillas JL
    Med Clin (Barc); 2016 Jun; 146(12):561.e1-8. PubMed ID: 27107729
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical outcomes in patients with Philadelphia chromosome-positive leukemia treated with ponatinib in routine clinical practice-data from a Belgian registry.
    Devos T; Havelange V; Theunissen K; Meers S; Benghiat FS; Gadisseur A; Vanstraelen G; Vellemans H; Bailly B; Granacher N; Lewalle P; De Becker A; Van Eygen K; Janssen M; Triffet A; Vrelust I; Deeren D; Mazure D; Bekaert J; Beck M; Selleslag D
    Ann Hematol; 2021 Jul; 100(7):1723-1732. PubMed ID: 33942128
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Patterns of surveillance for late effects of BCR-ABL tyrosine kinase inhibitors in survivors of pediatric Philadelphia chromosome positive leukemias.
    Smith SM; Sabnis HS; Lewis RW; Effinger KE; Bergsagel J; Patterson B; Mertens A; Sakamoto KM; Schapira L; Castellino SM
    BMC Cancer; 2021 Apr; 21(1):474. PubMed ID: 33926411
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CXCR2, a novel target to overcome tyrosine kinase inhibitor resistance in chronic myelogenous leukemia cells.
    Kim JH; Lee SJ; Kang KW; Lee BH; Park Y; Kim BS
    Biochem Pharmacol; 2021 Aug; 190():114658. PubMed ID: 34146540
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Collaborative cardiovascular management of patients with chronic myeloid leukemia on tyrosine kinase inhibitors.
    Kondapalli L; Worth S; Hawi R; Vachhani P; Arora G; Bhatia R; Lenneman CG
    Vasc Med; 2020 Jun; 25(3):246-254. PubMed ID: 32303152
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cardiovascular Toxicity in Cancer Patients Treated with Tyrosine Kinase Inhibitors: A Real-World Single-Center Experience.
    Novo G; Di Lisi D; Bronte E; Macaione F; Accurso V; Badalamenti G; Rinaldi G; Siragusa S; Novo S; Russo A
    Oncology; 2020; 98(7):445-451. PubMed ID: 32348984
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Management of vascular adverse events during tyrosine kinase inhibitors in patients with chronic myeloid leukemia].
    Takaku T
    Rinsho Ketsueki; 2020; 61(9):1018-1027. PubMed ID: 33162495
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: Cohort study of 477 patients.
    Jain P; Kantarjian HM; Ghorab A; Sasaki K; Jabbour EJ; Nogueras Gonzalez G; Kanagal-Shamanna R; Issa GC; Garcia-Manero G; Kc D; Dellasala S; Pierce S; Konopleva M; Wierda WG; Verstovsek S; Daver NG; Kadia TM; Borthakur G; O'Brien S; Estrov Z; Ravandi F; Cortes JE
    Cancer; 2017 Nov; 123(22):4391-4402. PubMed ID: 28743165
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Incidence and outcome of second malignancies in patients with chronic myeloid leukemia during treatment with tyrosine kinase inhibitors.
    Nakazato T; Iriyama N; Tokuhira M; Ishikawa M; Sato E; Takaku T; Sugimoto KJ; Fujita H; Fujioka I; Kimura Y; Aisa Y; Iwanaga E; Asou N; Kizaki M; Hatta Y; Komatsu N; Kawaguchi T
    Med Oncol; 2018 May; 35(7):99. PubMed ID: 29846829
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The multi-tyrosine kinase inhibitor ponatinib for chronic myeloid leukemia: Real-world data.
    Luciano L; Annunziata M; Attolico I; Di Raimondo F; Maggi A; Malato A; Martino B; Palmieri F; Pane F; Sgherza N; Specchia G
    Eur J Haematol; 2020 Jul; 105(1):3-15. PubMed ID: 32145037
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Variables associated with patient-reported outcomes in persons with chronic myeloid leukemia receiving tyrosine kinase-inhibitor therapy.
    Jiang Q; Wang HB; Yu L; Gale RP
    J Cancer Res Clin Oncol; 2017 Jun; 143(6):1013-1022. PubMed ID: 28251350
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Renin angiotensin system inhibitors reduce the incidence of arterial thrombotic events in patients with hypertension and chronic myeloid leukemia treated with second- or third-generation tyrosine kinase inhibitors.
    Mulas O; Caocci G; Stagno F; Bonifacio M; Annunziata M; Luciano L; Orlandi EM; Abruzzese E; Sgherza N; Martino B; Albano F; Galimberti S; Pregno P; Bocchia M; Castagnetti F; Tiribelli M; Binotto G; Gozzini A; Capodanno I; Fozza C; Luzi D; Efficace F; Simula MP; Scaffidi L; De Gregorio F; Elena C; Trawinska MM; Cattaneo D; Attolico I; Baratè C; Pirillo F; Sicuranza A; Gugliotta G; Stella R; Scalzulli E; Iurlo A; Foà R; Breccia M; La Nasa G
    Ann Hematol; 2020 Jul; 99(7):1525-1530. PubMed ID: 32474619
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Real-world analysis of tyrosine kinase inhibitor treatment patterns among patients with chronic myeloid leukemia in the United States.
    Henk HJ; Woloj M; Shapiro M; Whiteley J
    Clin Ther; 2015 Jan; 37(1):124-33. PubMed ID: 25467191
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Four-Dimensional Echocardiographic Evaluation of Left Ventricular Systolic Functions in Patients with Chronic Myeloid Leukaemia Receiving Tyrosine Kinase Inhibitors.
    Karakulak UN; Aladag E; Hekimsoy V; Sahiner ML; Kaya EB; Ozer N; Aksu S; Demiroglu H; Goker H; Buyukasik Y; Ozcebe O; Sayinalp N; Haznedaroglu IC
    Cardiovasc Toxicol; 2021 Mar; 21(3):216-223. PubMed ID: 33068232
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Vascular safety issues in CML patients treated with BCR/ABL1 kinase inhibitors.
    Valent P; Hadzijusufovic E; Schernthaner GH; Wolf D; Rea D; le Coutre P
    Blood; 2015 Feb; 125(6):901-6. PubMed ID: 25525119
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Current perspectives for the treatment of chronic myeloid leukemia.
    Aladağ E; Haznedaroğlu İC
    Turk J Med Sci; 2019 Feb; 49(1):1-10. PubMed ID: 30761815
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.